Centrum 7/6  banner

Entresto (sacubitril/valsartan)

Novartis Entresto granted expanded indication in chronic heart failure by FDA

Novartis Entresto granted expanded indication in chronic heart failure by FDA

EAST HANOVER, N.J.— Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved the following expanded indication for Entresto (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF)

PP_1170x120_10-25-21